Aravax presents PVX108 Phase 1 longitudinal immunology data at EAACI 2021.

13 July 2021, Melbourne, AUSTRALIA: Aravax, a clinical stage biotechnology company focused on

developing the first therapy for peanut allergy which is designed to be safe, effective and convenient,

shared further data from a follow up study of PVX108 Phase 1 trial subjects at the European Academy

of Allergy and Clinical Immunology (EAACI) Congress 2021 in Krakow, Poland.

Aravax Chief Scientific Officer Sara Prickett presented early data from longitudinal studies of Phase 1

trial participants which were followed up approximately 1 year after the completion of the main trial AVX-

001. The early data suggested that peanut-allergic subjects who had received active PVX108 therapy

had developed clinically relevant changes in their immune response to peanut protein. These included

changes in peanut-specific cellular responses, peanut-specific antibodies (immunoglobulins), and also

downstream tissue reactivity to peanut evaluated by skin-prick testing. None of these changes were

observed in subjects who received placebo. Studies are continuing with collaborating laboratories to

analyse additional samples and further characterise these changes. The follow-up study AVX-001-

EXT, conducted one year post treatment, also found no long-term safety signals related to PVX108.

Aravax previously reported Phase 1 trial results demonstrating that PVX108 has an excellent safety

profile in peanut-allergic subjects with prior anaphylaxis and current asthma.

PVX108 is a next-generation, allergen-specific immunotherapy using peptides that represent critical

fragments of peanut proteins to precisely target the T cells driving peanut allergy. Administered once

per month, therapy is designed to precisely induce tolerance to peanut protein without the safety

concerns constraining the use of the only registered therapy which uses natural extracts from peanuts.

The presence of whole peanut allergens in those extracts exposes patients to significant risks of

anaphylaxis (Chu et al. The Lancet 2019).

“These early longitudinal study results are very exciting and suggest that PVX108 had positive, long-

term-effects on the immune systems of peanut-allergic participants in this trial” said Aravax CSO, Dr

Sara Prickett. “We believe the next-generation technology underpinning PVX108 will overcome some

significant drawbacks associated with currently available treatments for peanut allergies. Aravax will

now focus on preparing for Phase 2 efficacy studies in Australia and the United States”.

Read More

Aravax_EAACI2021_press-release - final
Download PDF • 84KB